These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 12735887)

  • 1. [Metabolic syndrome, resistance to insulin and diabetes. What is hidden beneath the tip of the iceberg?].
    Costa B; Cabré JJ; Martín F
    Aten Primaria; 2003 Apr; 31(7):436-45. PubMed ID: 12735887
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypertension in people with diabetes and the metabolic syndrome: pathophysiologic insights and therapeutic update.
    Ganne S; Arora SK; Dotsenko O; McFarlane SI; Whaley-Connell A
    Curr Diab Rep; 2007 Jun; 7(3):208-17. PubMed ID: 17547838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the cardiometabolic syndrome.
    Sowers JR
    Clin Cornerstone; 2001; 4(2):17-23. PubMed ID: 11838324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The insulin resistance syndrome.
    Reaven GM
    Curr Atheroscler Rep; 2003 Sep; 5(5):364-71. PubMed ID: 12911846
    [No Abstract]   [Full Text] [Related]  

  • 5. Lipoprotein abnormalities in patients with type 2 diabetes and metabolic syndrome.
    Dickson-Humphries T; Bottenberg B; Kuntz S
    JAAPA; 2013 Jul; 26(7):13-8. PubMed ID: 23923282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. U-shaped association of sleep duration with metabolic syndrome and insulin resistance in patients with type 2 diabetes: the Fukuoka Diabetes Registry.
    Ohkuma T; Fujii H; Iwase M; Ogata-Kaizu S; Ide H; Kikuchi Y; Idewaki Y; Jodai T; Hirakawa Y; Nakamura U; Kitazono T
    Metabolism; 2014 Apr; 63(4):484-91. PubMed ID: 24411997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are there specific components of the insulin resistance syndrome that predict the increased atherosclerosis seen in type 2 diabetes mellitus?
    Golden SH; Chong R
    Curr Diab Rep; 2004 Feb; 4(1):26-30. PubMed ID: 14764276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of the metabolic syndrome as a strategy for preventing the macrovascular complications of type 2 diabetes: controversial issues.
    Aguilar-Salinas CA; Mehta R; Rojas R; Gómez-Pérez FJ; Olaiz G; Rull JA
    Curr Diabetes Rev; 2005 May; 1(2):145-58. PubMed ID: 18220590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
    Evans JL; Lin JJ; Goldfine ID
    Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of chronic hyperinsulinemia in insulin-resistant patients.
    Muntoni S; Muntoni S; Draznin B
    Curr Diab Rep; 2008 Jun; 8(3):233-8. PubMed ID: 18625122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift.
    Nolan CJ; Prentki M
    Diab Vasc Dis Res; 2019 Mar; 16(2):118-127. PubMed ID: 30770030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing atherosclerosis in patients with type 2 diabetes mellitus and metabolic syndrome.
    Venkatapuram S; Shannon RP
    Am J Ther; 2006; 13(1):64-71. PubMed ID: 16428924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome.
    Reusch JE
    Am J Cardiol; 2002 Sep; 90(5A):19G-26G. PubMed ID: 12231075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the metabolic syndrome: hypertension.
    Reynolds K; Wildman RP
    Curr Hypertens Rep; 2009 Apr; 11(2):150-5. PubMed ID: 19278605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The coming of age of the metabolic syndrome.
    Alexander CM
    Diabetes Care; 2003 Nov; 26(11):3180-1. PubMed ID: 14578259
    [No Abstract]   [Full Text] [Related]  

  • 16. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
    Aso Y; Wakabayashi S; Yamamoto R; Matsutomo R; Takebayashi K; Inukai T
    Diabetes Care; 2005 Sep; 28(9):2211-6. PubMed ID: 16123492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of the criteria used for the definition of metabolic syndrome in patients with type 2 diabetes mellitus].
    Picon PX; Zanatta CM; Gerchman F; Zelmanovitz T; Gross JL; Canani LH
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):264-70. PubMed ID: 16767292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of target organ damage and haemodynamic parameters over 4 years in patients with increased insulin resistance: the LOD-DIABETES prospective observational study.
    Gómez-Marcos MÁ; Recio-Rodríguez JI; Patino-Alonso MC; Agudo-Conde C; Rodríguez-Sanchez E; Maderuelo-Fernandez JA; Gómez-Sánchez L; Gomez-Sanchez M; García-Ortiz L;
    BMJ Open; 2016 Jun; 6(6):e010400. PubMed ID: 27251684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin resistance and the cluster of abnormalities related to the metabolic syndrome are associated with reduced glomerular filtration rate in patients with type 2 diabetes.
    De Cosmo S; Trevisan R; Minenna A; Vedovato M; Viti R; Santini SA; Dodesini AR; Fioretto P; Trischitta V
    Diabetes Care; 2006 Feb; 29(2):432-4. PubMed ID: 16443904
    [No Abstract]   [Full Text] [Related]  

  • 20. The clinical picture of metabolic syndrome. An update on this complex of conditions and risk factors.
    Doelle GC
    Postgrad Med; 2004 Jul; 116(1):30-2, 35-8. PubMed ID: 15274286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.